Debevoise Advises Guggenheim and J.P. Morgan as Financial Advisors to Bioverativ in its $11.6 Billion Sale to Sanofi

22 January 2018

Debevoise & Plimpton LLP is advising Guggenheim Securities and J.P. Morgan Securities Inc. as financial advisors to Bioverativ, a global biopharmaceutical company, in Bioverativ’s $11.6 billion sale to Sanofi.

The Debevoise team is led by partner Andrew L. Bab and includes associate Adam Garmezy.

Debevoise & Plimpton LLP is a premier law firm with market-leading practices, a global perspective and strong New York roots. We deliver effective solutions to our clients’ most important legal challenges, applying clear commercial judgment and a distinctively collaborative approach.